| Literature DB >> 34123373 |
Daniel A Smith1,2, Kate Simpson1, Matteo Lo Cicero3, Lucy J Newbury1,2, Philip Nicholas4, Donald J Fraser1,2, Nigel Caiger4, James E Redman2,3, Timothy Bowen1,2.
Abstract
This paper describes a straightforward electrochemical method for rapid and robust urinary microRNA (miRNA) quantification using disposable biosensors that can discriminate between urine from diabetic kidney disease (DKD) patients and control subjects. Aberrant miRNA expression has been observed in several major human disorders, and we have identified a urinary miRNA signature for DKD. MiRNAs therefore have considerable promise as disease biomarkers, and techniques to quantify these transcripts from clinical samples have significant clinical and commercial potential. Current RT-qPCR-based methods require technical expertise, and more straightforward methods such as electrochemical detection offer attractive alternatives. We describe a method to detect urinary miRNAs using diazo sulfonamide-modified screen printed carbon electrode-based biosensors that is amenable to parallel analysis. These sensors showed a linear response to buffered miR-21, with a 17 fM limit of detection, and successfully discriminated between urine samples (n = 6) from DKD patients and unaffected control subjects (n = 6) by differential miR-192 detection. Our technique for quantitative miRNA detection in liquid biopsies has potential for development as a platform for non-invasive high-throughput screening and/or to complement existing diagnostic procedures in disorders such as DKD. This journal is © The Royal Society of Chemistry.Entities:
Year: 2021 PMID: 34123373 PMCID: PMC8144888 DOI: 10.1039/d0ra09874d
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Fabrication of miRNA biosensors from screen printed carbon electrodes (SPCEs). The bare SPCE surface (a) is modified by electrochemical diazo sulfonic acid deposition to form an ANSA surface (b), which is further modified to a sulfonyl chloride (c) before addition of an amino terminated DNA strand complementary to the target miRNA, completing the biosensor (d). Hybridisation with the target miRNA (e) is detected electrochemically. For clarity, modification of only one of three working electrodes is shown.
Fig. 2The design of the multi-surface SPCE used as the basis of our miRNA biosensor. The process of screen printing is summarised: (a) the silver/silver chloride tracers and reference are printed, (b) the carbon working and auxiliary surfaces are printed, and (c) the insulating dielectric ink is printed to define each working electrode surface.
Fig. 3(Top) Example coulometric response following hybridisation of SPCE-biosensor with decreasing concentrations of miR-21. (Bottom) Reductive coulometric SPCE miR-21 biosensor response following hybridisation with varying concentrations of miR-21 over 4 separate experiments in [Fe(CN)6]3−/4− in 0.1 M KCl. Data are expressed as mean ± SEM (n = 11).
Fig. 4Reductive coulometry (Echem) and RT-qPCR (PCR) analysis of urinary miR-192 relative expression in DKD patients and control subjects. Data were normalised to miR-191 and are expressed as means ± SEM (n = 6).* p < 0.05.
A 450 readings from TMB substrate and stop solution ± streptavidin-HRP (S-HRP) for (a) non-biotinylated and biotinylated miR-21 biosensors and (b) non-biotinylated miR-21 or miR-223 biosensors hybridised with 10−7 M 5′-bio-miR-21
| Spectrophotometric analysis at 450 nm ( | |||||
|---|---|---|---|---|---|
| (a) Non-biotinylated or biotinylated (bio) miR-21 biosensors | (b) Non-biotinylated miR-21/miR-223 biosensors + 5′-bio-miR-21 | ||||
| Comp-miR-21 − S-HRP | Comp-miR-21 + S-HRP | 3′-Bio-comp-miR-21 + S-HRP | Comp-miR-21 − S-HRP | Comp-miR-223 + S-HRP | Comp-miR-21 + S-HRP |
| 0.000 | 0.010 ± 0.002 | 0.123 ± 0.014 | 0.000 | 0.008 ± 0.003 | 0.091 ± 0.006 |
Baseline response − streptavidin has been subtracted from the data, values are expressed as mean ± SD (n = 3). Oligonucleotides' details are provided elsewhere (ESI, Fig. S1).
Fig. 5TM-AFM images of the SPCE when (a) unmodified, (b) following ANSA deposition, (c) following DNA attachment, (d) after hybridisation with miRNA, (e) after submersion in untreated urine and (f) in urine treated with proteinase K and spin filtration. Key observation areas are shown by blue boxes.